Neotigason (Acitretin)

Acitretin binds to nuclear retinoic acid and retinoid X receptors, altering gene expression that controls keratinocyte differentiation and proliferation. This results in reduced epidermal hyperplasia, improved skin barrier function, and decreased inflammatory cytokine production.

The specific dose of Neotigason is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Neotigason is classified as Pregnancy Category X because it is highly teratogenic. It must not be used during pregnancy or by women who may become pregnant. Safety during breastfeeding has not been established, and use is generally avoided.

To order Neotigason, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other systemic options such as methotrexate or biologic agents, acitretin offers a non‑biologic oral alternative that directly targets keratinocyte differentiation. It does not require injection but carries a higher risk of teratogenicity and lipid abnormalities, whereas biologics often have different safety profiles and administration routes.

Neotigason tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Neotigason is taken orally as a tablet, usually with a full glass of water. It may be taken with or without food, but consistent administration with respect to meals can help reduce gastrointestinal discomfort.

The most serious risks include teratogenicity (birth defects), hepatotoxicity (liver injury), severe hyperlipidemia (dangerously high cholesterol or triglycerides), and pseudotumor cerebri (increased intracranial pressure). Patients should be monitored regularly for these conditions.

Neotigason should not be used by pregnant women, women planning pregnancy, children, patients with severe liver disease, uncontrolled hyperlipidemia, or anyone unable to adhere to strict contraception requirements during and after therapy.